Lemaitre Vascular, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
July 29, 2021 at 04:26 pm EDT
Share
LeMaitre Vascular, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 40.670 million compared to USD 24.851 million a year ago. Operating income was USD 11.106 million compared to USD 4.872 million a year ago. Net income was USD 8.299 million compared to USD 3.500 million a year ago. Basic earnings per share from continuing operations was USD 0.4 compared to USD 0.17 a year ago. For the half year, sales was USD 76.553 million compared to USD 55.402 million a year ago. Operating income was USD 19.051 million compared to USD 9.225 million a year ago. Net income was USD 14.228 million compared to USD 6.674 million a year ago. Basic earnings per share from continuing operations was USD 0.69 compared to USD 0.33 a year ago. Diluted earnings per share from continuing operations was USD 0.68 compared to USD 0.33 a year ago.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.